FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alone in treating patients with prostate cancer that is sensitive to androgen-deprivation therapy (ADT) and has spread from where it first started (primary site) to other places in the body (metastatic). Prostate cancer is the second leading cause of cancer death among men in the United States, despite the approval of several life-prolonging treatments by the Food and Drug Administration. However, ov

Trial Details

NCT ID

NCT06244004

Phase

PHASE2

Sponsor

Northwestern University

Status

RECRUITING

Cancer Type

Hormone-Sensitive Prostate Cancer

Interventions

Antiandrogen Therapy
Bone Scan
Computed Tomography
Cytotoxic Chemotherapy
FDG-Positron Emission Tomography
Radiation Therapy

Locations (sample)

Chicago, Illinois, United States|41.85003,-87.65005
DeKalb, Illinois, United States|41.92947,-88.75036
Geneva, Illinois, United States|41.88753,-88.30535
Oak Brook, Illinois, United States|41.83281,-87.92895
Orland Park, Illinois, United States|41.63031,-87.85394

Key Eligibility Criteria

Patients must have metastatic prostate cancer on conventional imaging (CT scan, MRI, and/or bone scan).
Note; Patients who had metastatic disease on conventional imaging prior to beginning ADT, but which has now resolved, are still eligible if they me…
Patients must be ≥ 18 years of age at the time of informed consent.
Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →